
See how conventional and slow release lithium compare



The authors of two recent comparisons^{1,2} between Camcolit and the two types of slow release lithium concluded that there is no therapeutic basis for the administration of slow release lithium preparations in preference to Camcolit.

As their studies show, there is no significant difference in the rate of absorption or excretion of the two types, despite the disparity in their rates of release in vitro.

The authors do state, however,²

that there are sound economic grounds for preferring Camcolit.

In fact, slow release lithium costs almost three times as much—so in the treatment and prophylaxis of mania, manic-depressive illness and recurrent depression. Camcolit offers maximum therapeutic effect at minimum cost.

Camcolit is supplied in tablets of lithium carbonate BP 250mg to allow full flexibility of dosage. Packed in securitainers of 100 and 1000.

Camcolit Equal effect - at almost one-third of the cost

Further information on request from: 1200K Camden Chemical Company Limited, 26-28 Bedford Row, London WC1R 4HJ



Anafranil is the most recent addition to the Geigy range of psychotropic drugs. In addition to its use in depression, where it has proved to be effective both by the oral route and by intravenous infusion (in the more seriously depressed patient), Anafranil is becoming established as a leading drug treatment for obsessional and phobic disorders. We will be pleased to forward further information relating to the use of Anafranil in the treatment of depression and phobic and obsessional disorders on request.

Anafranil is 3-chloro-5-(3-dimethylaminopropyl)-10, 11-dihydro 5H dibenz [b, f] azepine (clomipramine) hydrochloride

Full prescribing information is available.

Geigy Pharmaceuticals, Macclesfield, Cheshire SK10 2LY

Anafranil[®] in depression

"The most striking finding however, was the number of patients who showed spectacular improvement and who had been ill for considerable periods of time. By and large this group were of a chronic grumbling type who sought much and constant medical attention and yet did not reward the doctor by getting better."

Clomipramine (Anafranii) in the treatment of chronic intractable depression. Paper read at the Fifth World Congress of Psychiatry, Mexico D.F. 1971.

"The difference between the proportion of patients in hospital who improved when treated with electroconvulsive therapy, conventional antidepressant drug therapy and intravenous infusion of clomipramine was statistically significant in favour of the last mentioned treatment. Patients on clomipramine as a group needed fewer treatments and returned to work more rapidly than did their counterparts having electroconvulsive therapy."

A new adjunct to the treatment and management of depression ; intravenous infusion of clomipramine (Anafranil). S. Afr. med. J., 45, 168 (1971)

"72% (of 57 patients) showed a very good or good response and 96% made some improvement. This compares very favourably with the response of similar groups of severely depressed patients to E.C.T., and it is postulated that intravenous chlorimipramine can be offered as an alternative form of treatment."

"Oral group : 78 per cent showed a very good or good response and 96 per cent improved to some extent. This also compared favourably with the results obtained with other antidepressant drugs in similar groups of patients."

Parenteral and oral chlorimipramine treatment of depressive states. Brit. J. Psychiat., 122, 189 (1973)

Anafranil[®] in obsessional/phobic disorders

"Clomipramine has the two distinct properties of being an anti-depressive and an anti-obsessional drug."

Clomipramine (Anafranil) in the treatment of obsessional states : A psychiatrists view. J. Int. Med. Res., 3 (Supp 1) 83 (1975)

"Obsessional illnesses have always been notorious for their resistance to treatment and phobic states, especially, when they are diffuse and polysymptomatic, do not respond always to deconditioning or flooding techniques A treatment which offers brevity with a 70% chance of disappearance or considerable reduction in symptoms is worth offering to patients as a first choice of therapies."

Clomipramine (Anafranil) in the treatment of obsessional illnesses and phobic anxiety states, J. Int. Med. Res., 1, 403 (1973)

"It is our view that clomipramine not only gives good results in severe and moderate depressive states, but it is emerging as the treatment of choice in obsessive compulsive disorders and phobic states."

Letter, Treating phobias. World Medicine, 7, 11: 15 (1972)

"The mode of action of Anafranil is unknown but without doubt it appears to exert a beneficial effect on neurotic responses in general and phobic and obsessional states in particular."

An investigation into the use of Anafranil in phobic and obsessional disorders. Scot. med. J., 20 (Supp), 61 (1975)

Indications

Tryptizol' is recommended in the treatment of depression including that accom-panied by anxiety. panied by anxiety. Tryptizol' may be used successfully in depression that is a manifestation of

psychosis or neurosis, whether endogenous or reactive in nature. Endogenous depression is more likely to be alleviated than are other depressive states. Tryptizol' has an anxiety-reducing and sedative component to its action which is particularly helpful in alleviating anxiety or agitation that often accompanies

depression. Thus been used with benefit in depressions of long or short duration, and with a wide range of intensity. As with other psychotherapeutic agents, all patients do not respond to the same degree. Some patients respond promptly, while others may require up to 30 days to obtain benefit. Lack of response may occur occasionally.

Depressive reactions and associated anxiety accompanying chronic illness may be relieved by 'Tryptizol'.

Dosage and administration

Socials: and administration Start with one 75 mg capsule at bedtime and increase, if necessary, to two capsules at bedtime or one in the morning and one at night. The 75 mg capsule may also be used as maintenance therapy. The anxiety-reducing and sedative effect is usually rapidly apparent. The antidepressant activity may be seen within 3 or 4 days or may take up to 30 days to develop adequartely.

develop adequately.

Contra-indications

Hypersensitivity to amitriptyline, concomitant use with a monoamine oxidase inhibitor (see 'Precautions'), during the acute recovery phase following myocardial infarction. See 'Usage in Pregnancy' under 'Precautions'.

Precautions

Combined use of antidepressants having varying modes of activity requires thorough knowledge of pharmacology of all agents. Allow minimum of 14 days to elapse following discontinuation of MAO inhibitors and introduction of Tryptizol'. (Hyperpyretic crises, severe convulsions and deaths have occurred when tricyclic antidepressants and MAOI drugs were given simultaneously.) Introduce 'Tryptizol' cautiously and gradually increase until optimum response is

When amitriptyline is used to treat the depressive component of schizophrenia, psychotic symptoms may be aggravated. If used in manic-depressive psychosis a shift towards the manic phase may occur. Paranoid delusions, with or with-out associated hostility may be exaggerated. (In such circumstances either reduce dose of amitriptyline or add major tranquillising drug.) The possibility of suicide in depressed patients remains during treatment and until significant remission occurs. This type of patient should not have easy access to large quantities of the drug.

Concurrent administration of amitriptyline and electroconvulsive therapy may increase the hazards of therapy and therefore chould be limited to patients for may increase the haz whom it is essential.

Which it is essential. Use with caution in patients with history of scizures, crinary retention, or increased intra-ocular pressure. With marrow-angle glaucoma, even average doses may precipitate an attack. Closely supervise treatment in hyperthyroid patients, those receiving thyroid medication, anticholinergic or sympathomimetic drugs, including adrenaline combined with local anaesthetics (careful adjustments of doage are required) and those who receive large doses of ethchlorvynol concurrently. concurrently.

It may enhance the response to alcohol and the effects of barbiturates or other CNS depressants. Alertness may be impaired in some patients (activities made hazardous by this diminished alertness should be avoided).

Patients with cardiovascular disorders should be watched closely. Tricyclic anti-depressant drugs have been reported to produce arrhythmias, sinus tachycardia, and prolongation of the conduction time, myocardial infarction and stroke. Amitriptyline may block the antihypertensive action of guanethidine or similarly acting compounds.

Discontinue amitriptyline several days before elective surgery, if possible. Both elevation and lowering of blood sugar levels have been reported.

Not recommended for depressed patients under 12 years of age. Safe use during pregnancy has not been established. Weigh benefits against possible hazards to mother and child when administered to pregnant or possibly pregnant women and to nursing mothers.

Side effects

Note: Included in the listing which follows are a few adverse reactions which have not been reported with this specific drug. However, pharmacological similarities among the tricyclic antidepressant drugs require that cach of the reactions be considered when amitriptyline is administered.

reactions be considered when amitriptyline is administered. Cardiovascular: Hypotension, hypertension, tachycardia, palpitations, myo-cardial infarction, arrhythmias, heart block, stroke. CNS and neuroonuscullar: Confusional states, disturbed concentration, disorientation, delusions, halbucinations, excitement, anxiety, restlessness, insomnia, nightmares, numbness, tingling, and paraesthesiae of the extremities, peripheral neuropathy, incoordination, ataxia, tremors, scieures, alteration of EEG patterns, extrapyramidal symptoms, tinnitus. Anticholinergie: Dry mouth, blurred vision, disturbance of accommodation, constipation, paralytic ileus, urinary retention, dilatation of urinary tract.

Allergic: Skin rash, urticaria, photosensitisation, oedema of face and tongue.

Haematological: Bone-marrow depression including agranulocytosis, leucopenia, cosinophilia, purpura, thrombocytopenia.

Gastro-Intestinal: Nausca, epigastric distress, vomiting, anorexia, stomatitis, peculiar taste, diarrhoea, parotid swelling, black tongue, rarely hepatitis (including altered liver function and jaundice).

Endocrine: Testicular swelling and gynaccomastia in the male, breast enlarge-ment and galactorrhoea in the female, increased or decreased libido, clevation or lowering of blood sugar levels.

suvering of blood sugar revers. Others Diziness, weakness, fatigue, headache, weight loss or gain, increased perspiration, urinary frequency, mydriasis, drowsiness, alopecia. Withdar wai symptomus: Abrupt cessation of treatment after prolonged admini-stration may produce nausea, headache, and malaise. These are not indicative of addictioned to the state of the st addiction

Presentation

SD

Trypticol' 75, slow-release capsules marked 'MSD 649' containing 75 mg ami-triptyline hydrochloride BP as a pelleted formulation in bottles of 100. Product ficence number: 0025/0116.

Detailed information is available to physicians on request. @ denotes registered trademark.





Merck Sharp & Dohme Limited

Hoddesdon, Hertfordshire, ENII oBU https://doi.org/10.1017/S0033291700015750 Published online by Cambridge University Press 76-4000

Tryptizol[®]75 once-a-day treats depressive insomnia

When depression causes sleep disturbances, 'Tryptizol' 75 can help ensure a good night's sleep. 'Tryptizol' 75 is usually taken as a single dose at bedtime.

'Tryptizol' 75 offers a single, convenient daily dose with less need to prescribe hypnotics.




Control the aggressive destructive patient



with DEOLACTOL

Full information is available on request 'Neulactil' is a trade mark of May & Baker Ltd Dagenham Essex RM107XS for its preparations of pericyazine



'Neulactil' is a most effective treatment for unmanageable, disruptive behaviour at every age. It has been found extremely useful in controlling injurious, impulsive acts and in improving sociability in demented geriatric and in chronic psychotic patients, in retarded children and in antisocial adolescents, and also for the relief of severe anxiety. On 'Neulactil', in-patients become more friendly and helpful to the nursing staff and others within the ward, and occupational therapy progresses.

MA3336

NOTES FOR CONTRIBUTORS

PAPERS Papers for publication should be addressed to the Editor, Professor Michael Shepherd, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE58AF. Contributors should send at least three copies of the text, tables, and figures. Copies other than the first may be xeroxed. The S.I.system should be adopted for text and figures. A short summary of about 50 words should be provided at the beginning of each article. Foreign quotations and phrases should be followed by a translation. Submission of a paper will be held to imply that it contains original work that has not been previously published and that it is not being submitted for publication elsewhere.

In addition to longer articles, the Editor is prepared to accept preliminary communications of up to about 1,500 words.

Manuscripts must be typewritten on one side of the paper in double-spacing with wide margins. The following information must be given on a single separate sheet: (1) title and short title for running head (not more than 100 characters); (2) authors' names, and (3) department in which work was done. Footnotes on the same sheet should list: (i) the authors' present addresses if different from departments in which work was done; (ii) name and address of the author to whom correspondence should be addressed; (iii) receipt of grants. Authors who would like a reprint address to be printed should include this on their manuscript.

REFERENCES (1) In the text these should follow the Harvard system – that is, name followed by date: Brown (1970). If there are more than two authors the first author's name followed by *et al.* should be used, even the first time that the reference appears. (2) The list of references should be typed in alphabetical order on a separate sheet and should appear as follows: Brown, J., Williams, E. & Wright, H. (1970). Treatment of heroin addiction. *Psychological Medicine* 1, 134–136. Journal titles should be given in full.

Books should be cited as follows: Brown, J. (1970). Psychiatric Research. Smith: Glasgow.

ILLUSTRATIONS Only essential figures and tables should be included. *Photographs* Unmounted photographs on glossy paper should be provided. Magnification scales, if necessary, should be lettered on these. Where possible, prints should be trimmed to column width (i.e. $2\frac{3}{4}$ in.). *Diagrams* These will usually be reduced to $2\frac{3}{4}$ in. wide. Lettering should be in either Letraset or stencil, and care should be taken that lettering and symbols are of comparable size. Illustrations should not be inserted in the text, they should be marked on the back with figure numbers, title of paper, and name of author. All photographs, graphs, and diagrams should be referred to as figures and should be numbered consecutively in the text in Arabic numerals. The legends for illustrations should be typed on a separate sheet. *Tables* Tables should be numbered consecutively in the text in Arabic numerals and each typed on a separate sheet.

PROOFS AND OFFPRINTS Page proofs will be sent to the senior author. Corrections other than printer's errors may be charged to the author. Fifty offprints of each paper are supplied free; additional offprints are available according to a scale of charges if they are ordered when the proof is returned.

Psychological Medicine

Volume 6 Number 3 August 1976

CONTENTS

EDITORIALS	
Kuru The role of rating scales in psychiatry	page 343 347
HILL, C. AND SHEPHERD, M. The case of Arise Evans: A historico-psychiatric study	351
FELDBERG, W. Possible association of schizophrenia with a disturbance in prostaglandin metabolism: a physiological hypothesis	359
WAKELING, A., MARSHALL, J. C., BEARDWOOD, C. J., DE SOUZA, V. F. A. AND RUSSELL, The effects of clomiphene citrate on the hypothalmic-pituitary-gonadal axis in anorexia nervosa	g. f. м. 371
SARAN, B. J. AND RUSSELL, G. F. M. The effects of administering lithium carbonate on the balance of Na, K and water in manic-depressive patients	381
VAN DEN BURG, W., VAN PRAAG, H. M., BOS, E. R. H., PIERS, D. A., VAN ZANTEN, A. K. And Doorenbos, H.	
THR by slow, continuous infusion: an antidepressant?	393
BRIDGES, P. K., BARTLETT, J. R., SEPPING, P., KANTAMANENI, B. D. AND CURZON, G. Precursors and metabolites of 5-hydroxytryptamine and dopamine in the ventricular cerebrospinal fluid of psychiatric patients	399
WILES, D. H., KOLAKOWSKA, T., MCNEILLY, A. S., MANDELBROTE, B. M. AND GELDER, M Clinical significance of plasma chlorpromazine levels. I. Plasma levels of the drug, some o its metabolites and prolactin during acute treatment	r. G. of 407
JACOBSON, S., BAGLEY, C. AND REHIN, A. Clinical and social variables which differentiate suicide, open and accident verdicts	417
BAGLEY, C. AND JACOBSON, S. Ecological variation of three types of suicide	423
BAGLEY, C., JACOBSON, S. AND REHIN, A. Completed suicide: a taxonomic analysis of clinical and social data	429
COPELAND, J. R. M., KELLEHER, M. J., KELLETT, J. M. AND GOURLEY, A. J. WITH GURLAND, B. J., FLEISS, J. L. AND SHARPE, L. A semi-structured clinical interview for the assessment of diagnosis and mental state in the elderly: the Geriatric Mental State Schedule. I. Development and reliability	he 439
GURLAND, B. J., FLEISS, J. L., GOLDBERG, K. AND SHARPE, L. WITH COPELAND, J. R. M., KELLEHER, M. J. AND KELLETT, J. M. A semi-structured clinical interview for the assessment of diagnosis and mental state in the elderly: the Geriatric Mental State Schedule. II. A factor analysis	he 451
BELLINI, M. AND TANSELLA, M. Obsessional scores and subjective general psychiatric complaints of patients with duoden ulcer or ulcerative colitis	al 461
WHITEHEAD, A. The prediction of outcome in elderly psychiatric patients	469
PAYKEL, E. S. AND TANNER, J. Life events, depressive relapse and maintenance treatment	481
PALLIS, D. J. AND SAINSBURY, P. The value of assessing intent in attempted suicide	487
SERGEANT, H. Rehabilitation of psychiatric patients who stayed in hospital more than one year	493
RESEARCH REPORT Institute of Psychiatry Department of Child and Adolescent Psychiatry	505
BOOK REVIEWS	517

© Cambridge University Press 1976

CAMBRIDGE UNIVERSITY PRESS Bentley House, 200 Euston Road, London NW1 2DB 32 East 57th Street, New York, N.Y. 10022

Printed in Great Britain at the University Printing House, Cambridge